Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study
Background - This detailed analysis further characterizes the safety profile of talazoparib plus enzalutamide in the ongoing randomized, phase III TALAPRO-2 study in patients with metastatic castration-resistant prostate cancer (mCRPC). In both the all-comers and homologous recombination repair (HRR...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
December 2024
|
| In: |
European journal of cancer
Year: 2024, Jahrgang: 213, Pages: 1-9 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2024.115078 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.ejca.2024.115078 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804924012097 |
| Verfasserangaben: | Arun A. Azad, Karim Fizazi, Nobuaki Matsubara, Fred Saad, Ugo De Giorgi, Jae Young Joung, Peter C.C. Fong, Robert J. Jones, Stefanie Zschäbitz, Jan Oldenburg, Neal D. Shore, Curtis Dunshee, Joan Carles, Andre P. Fay, Xun Lin, Liza DeAnnuntis, Nicola Di Santo, Michael A. Zielinski, Neeraj Agarwal |
Search Result 1